BioSpace News Archive

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics announced an oral, encore presentation of clinical data from patients with sickle cell disease or transfusion-dependent beta-thalassemia treated with the investigational therapy exagamglogene autotemcel in CLIMB-111 or CLIMB-121 and followed in CLIMB-131, a long-term follow-up study.

Adaptive Biotechnologies Corporation announced new data demonstrating the strengths of Adaptive’s next-generation sequencing -based clonoSEQ® Assay in measuring minimal residual disease in blood cancer patients.

Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer, announced positive safety and efficacy data from the Company’s ongoing Phase 1 study of ADI-001 for the potential treatment of relapsed or refractory B-cell NHL.

Precision BioSciences, a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing therapies, presented a novel, product-attributes analysis of its lead CD19 allogeneic CAR T candidate, Azercabtagene Zapreleucel that shows a relationship between CAR T cell composition and effective cell dose with pharmacokinetics, pharmacodynamics, and clinical outcomes.

Syros Pharmaceuticals announced data from the safety lead-in portion of its ongoing SELECT-AML-1 Phase 2 trial evaluating tamibarotene, an oral, selective retinoic acid receptor alpha agonist, in combination with venetoclax and azacitidine in newly diagnosed, unfit patients with acute myeloid leukemia and RARA gene overexpression.

Innate Pharma SA presented data from a preliminary analysis of the TELLOMAK Phase 2 trial demonstrating clinical activity and a favorable safety profile for lacutamab, a first-in-class anti-KIR3DL2 humanized cytotoxicity-inducing antibody, in patients with advanced Sézary syndrome, a form of T cell lymphoma.

Sutro Biopharma, Inc. announced that its research collaborators at Fred Hutchinson Cancer Research Center presented data from the Compassionate Use Program on anti-leukemic activity of STRO-002 in pediatric patients with relapsed/refractory CBFA2T3-GLIS2 acute myeloid leukemia, commonly known as RAM phenotype AML, in an oral presentation at the 64th ASH Annual Meeting and Exposition in New Orleans, LA.

argenx SE announced that data from its Phase 3 ADVANCE trial will be presented during the plenary session at the 64th American Society of Hematology Annual Meeting & Exposition in New Orleans, LA.

The Janssen Pharmaceutical Companies of Johnson & Johnson announced new results from a cohort of the Phase 1b MajesTEC-2 study of TECVAYLI™, a first-in-class, BCMAxCD3 bispecific T-cell engager antibody, in combination with DARZALEX FASPRO® and lenalidomide.

Affimed N.V. provided a data update from the ongoing phase 1/2 study of the Company’s lead innate cell engager AFM13 precomplexed with cord blood-derived natural killer cells in patients with CD30-positive relapsed or refractory Hodgkin and Non-Hodgkin lymphomas.